JP2023525960A - 骨に標的治療薬を送達するための組成物および方法 - Google Patents

骨に標的治療薬を送達するための組成物および方法 Download PDF

Info

Publication number
JP2023525960A
JP2023525960A JP2022562617A JP2022562617A JP2023525960A JP 2023525960 A JP2023525960 A JP 2023525960A JP 2022562617 A JP2022562617 A JP 2022562617A JP 2022562617 A JP2022562617 A JP 2022562617A JP 2023525960 A JP2023525960 A JP 2023525960A
Authority
JP
Japan
Prior art keywords
seq
sequence
polypeptide
chimeric polypeptide
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525960A5 (cg-RX-API-DMAC7.html
Inventor
アルバレス,ルイス
ステュアート,ディヴィッド
パク,ヘヨン
ヘイル,トッド
Original Assignee
セラダプティブ インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラダプティブ インク filed Critical セラダプティブ インク
Publication of JP2023525960A publication Critical patent/JP2023525960A/ja
Publication of JP2023525960A5 publication Critical patent/JP2023525960A5/ja
Priority to JP2025152835A priority Critical patent/JP2026004340A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2022562617A 2020-04-15 2021-04-14 骨に標的治療薬を送達するための組成物および方法 Pending JP2023525960A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025152835A JP2026004340A (ja) 2020-04-15 2025-09-12 骨に標的治療薬を送達するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063010639P 2020-04-15 2020-04-15
US63/010,639 2020-04-15
PCT/US2021/027230 WO2021211683A2 (en) 2020-04-15 2021-04-14 Compositions and methods for targeted therapeutic delivery to bone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025152835A Division JP2026004340A (ja) 2020-04-15 2025-09-12 骨に標的治療薬を送達するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2023525960A true JP2023525960A (ja) 2023-06-20
JP2023525960A5 JP2023525960A5 (cg-RX-API-DMAC7.html) 2024-04-23

Family

ID=78084414

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562617A Pending JP2023525960A (ja) 2020-04-15 2021-04-14 骨に標的治療薬を送達するための組成物および方法
JP2025152835A Pending JP2026004340A (ja) 2020-04-15 2025-09-12 骨に標的治療薬を送達するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025152835A Pending JP2026004340A (ja) 2020-04-15 2025-09-12 骨に標的治療薬を送達するための組成物および方法

Country Status (10)

Country Link
US (2) US12264187B2 (cg-RX-API-DMAC7.html)
EP (1) EP4135750A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023525960A (cg-RX-API-DMAC7.html)
KR (1) KR102821039B1 (cg-RX-API-DMAC7.html)
CN (1) CN115916239A (cg-RX-API-DMAC7.html)
AU (1) AU2021254751B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022020809A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180156A1 (cg-RX-API-DMAC7.html)
TW (1) TW202203961A (cg-RX-API-DMAC7.html)
WO (1) WO2021211683A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CA3115298A1 (en) 2018-10-12 2020-04-16 Theradaptive, Inc. Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
BR112022020809A2 (pt) 2020-04-15 2023-02-23 Theradaptive Inc Composições e métodos para entrega terapêutica direcionada ao osso
AU2024278702A1 (en) * 2023-05-30 2026-01-15 Theradaptive, Inc. Compositions comprising an interleukin and a calcium compound for treating a cancer
WO2025166305A1 (en) * 2024-02-02 2025-08-07 Theradaptive, Inc. Bone formation compositions and methods of use
CN120789330A (zh) * 2025-08-04 2025-10-17 中国人民解放军总医院第四医学中心 一种外科钛合金融合器活性涂层的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500276A (ja) * 2010-12-06 2014-01-09 マサチューセッツ インスティテュート オブ テクノロジー リン酸三カルシウム結合ペプチド及びその使用
JP2022520139A (ja) * 2018-10-12 2022-03-29 セラダプティブ インク β-リン酸三カルシウム結合配列を含むポリペプチドとその使用
JP2022545185A (ja) * 2019-08-20 2022-10-26 セラダプティブ インク 骨インプラントにおける係留可能なタンパク質の送達のための材料

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4880610A (en) 1988-04-20 1989-11-14 Norian Corporation In situ calcium phosphate minerals--method and composition
US5152791A (en) 1989-12-07 1992-10-06 Olympus Optical Co., Ltd. Prosthetic artificial bone having ceramic layers of different porosity
US5491082A (en) 1991-03-18 1996-02-13 Director-General Of Agency Of Industrial Science And Technology Plasminogen activator covalently bonded to a porous body of β-tricalcium phosphate
US7008634B2 (en) 1995-03-03 2006-03-07 Massachusetts Institute Of Technology Cell growth substrates with tethered cell growth effector molecules
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
DE60020526T2 (de) 1999-02-04 2006-05-11 SDGI Holdings, Inc., Wilmington Osteogene pastenzusammensetzungen und ihre verwendung
KR20010085996A (ko) * 1999-09-03 2001-09-07 스티븐 엠. 오드레 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
JP4993834B2 (ja) 2000-06-29 2012-08-08 ノース ショア−ロング アイランド ジューイッシュ ヘルス システム 細胞増殖および血管形成の調節物質、その使用方法および特定方法
US6949251B2 (en) 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
US20040197892A1 (en) 2001-04-04 2004-10-07 Michael Moore Composition binding polypeptides
US20030113714A1 (en) 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
WO2003072593A2 (en) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US20050084962A1 (en) 2003-08-20 2005-04-21 Bruce Simon Methods of treatment using electromagnetic field stimulated stem cells
ATE474589T1 (de) 2003-10-29 2010-08-15 Univ Ramot Angiogene peptide und ihre verwendungen
US7572766B2 (en) 2004-06-16 2009-08-11 Affinergy, Inc. IFBMs to promote the specific attachment of target analytes to the surface of orthopedic implants
WO2006012414A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Novel polyadenylation signal for use in expression vectors
US7871978B2 (en) 2004-11-04 2011-01-18 University Of Virginia Patent Foundation Bone tropic peptides
WO2006062776A2 (en) 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
US20060193916A1 (en) 2005-01-07 2006-08-31 Acologix, Inc. Formulations of peptides for periodontal and dental treatments
US8137664B2 (en) 2005-02-02 2012-03-20 Sdgi Holdings, Inc. Method and kit for repairing a defect in bone
ATE514712T1 (de) * 2005-12-26 2011-07-15 Yantai Zhenghai Bio Technology Co Ltd Aktivierte collagen-gerüstmaterialien und ihre speziellen kondensierten aktiven restorationsfaktoren
US7592009B2 (en) 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
US9295755B2 (en) 2006-10-18 2016-03-29 Wisconsin Alumni Research Foundation Multilayer tissue regeneration system
US7977313B2 (en) 2007-04-27 2011-07-12 Affinergy, Inc. Methods and compositions for promoting localization of pharmaceutically active agents to bone
US8075562B2 (en) 2007-06-25 2011-12-13 Wisconsin Alumni Research Foundation Controlled release of biopharmaceutical growth factors from hydroxyapatite coating on bioresorbable interference screws used in cruciate ligament reconstruction surgery
WO2009025719A1 (en) 2007-08-03 2009-02-26 University Of Massachusetts Medical School Polymer compositions for biomedical and material applications
WO2009108934A2 (en) 2008-02-28 2009-09-03 Osteotherapeutics, L.L.C. Injectable calcium phosphate cememts formulated with bioactive agents and methods for making same
JP5737707B2 (ja) 2008-03-04 2015-06-17 クリスタル バイオサイエンス インク.Crystal Bioscience Inc. ゲル状マイクロドロップ組成物およびその使用方法
US8158366B2 (en) 2008-04-07 2012-04-17 Auburn University Methods of identifying peptides and compositions that bind to oocytes in a species-specific manner
US20100049322A1 (en) 2008-08-19 2010-02-25 Warsaw Orthopedic, Inc. Osteochondral repair implants and methods
GB0818255D0 (en) * 2008-10-06 2008-11-12 Agency Science Tech & Res Isolation and identification of glycosaminoglycans
WO2010051032A1 (en) 2008-10-31 2010-05-06 Synthes Usa, Llc Method and device for activating stem cells
WO2010052715A2 (en) 2008-11-07 2010-05-14 Ramot At Tel Aviv University Ltd. Devices and methods for local treatment of cardiovascular diseases
US20100260673A1 (en) 2009-04-10 2010-10-14 Qizhen Cao Phage display peptide probes for imaging early responses to antiangiogenic treatment
US8420774B2 (en) 2009-12-01 2013-04-16 Wisconsin Alumni Research Foundation Decorating hydroxyapatite biomaterials with modular biologically active molecules
CA2793671A1 (en) 2010-03-19 2011-09-22 Lifenet Health Bmp-2 peptides & methods of use
US8778869B2 (en) 2010-06-09 2014-07-15 Wisconsin Alumni Research Foundation Tissue regeneration system
WO2012083366A1 (en) 2010-12-21 2012-06-28 Prosthexis Pty Ltd Prosthetic menisci and method of implanting in the human knee joint
CN102532272A (zh) 2011-12-29 2012-07-04 陕西师范大学 HepG2细胞表面特异性结合的多肽
CN104193803B (zh) 2014-07-25 2016-08-17 河南科技大学 鸭肝炎病毒i型vp1蛋白抑制肽及其应用
US20160159869A1 (en) 2014-12-09 2016-06-09 Northwestern University Bmp-2-binding peptide amphiphile nanofibers
EP3564371B1 (en) 2015-12-04 2020-05-27 Caribou Biosciences, Inc. Engineered nucleic-acid targeting nucleic acids
US11802873B2 (en) 2017-05-29 2023-10-31 Charité Universitätsmedizin Berlin CD8 T cell subsets as a biomarker for predicting non-fusion after spinal fusion surgery
US10675330B2 (en) 2018-03-21 2020-06-09 Warsaw Orthopedic, Inc. Injectable bone morphogenetic protein
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
CN110746500A (zh) 2018-07-24 2020-02-04 浙江瑞谷生物科技有限公司 一种编码重组人骨形态发生蛋白质-2的氨基酸序列
US20200102458A1 (en) 2018-09-28 2020-04-02 Icl Specialty Products Inc. Cool Roof Coating Containing Multifunctional Additive
CA3124677A1 (en) 2018-12-25 2020-07-02 Orthorebirth Co., Ltd. A bone regeneration material having a cotton-wool like structure formed of a plurality of electrospun fibers
US20220096600A1 (en) 2019-02-07 2022-03-31 Baylor College Of Medicine Periosteal skeletal stem cells in bone repair
WO2021194604A2 (en) * 2020-03-06 2021-09-30 Theradaptive, Inc. Therapeutic compositions comprising graft materials and beta-tcp binding peptides and uses thereof
BR112022020809A2 (pt) 2020-04-15 2023-02-23 Theradaptive Inc Composições e métodos para entrega terapêutica direcionada ao osso
TWI794842B (zh) 2020-06-21 2023-03-01 日商奧梭瑞貝斯股份有限公司 骨誘導性的骨再生材料及其製備方法
WO2022182749A2 (en) 2021-02-24 2022-09-01 Theradaptive, Inc. Ceramic compositions and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500276A (ja) * 2010-12-06 2014-01-09 マサチューセッツ インスティテュート オブ テクノロジー リン酸三カルシウム結合ペプチド及びその使用
JP2022520139A (ja) * 2018-10-12 2022-03-29 セラダプティブ インク β-リン酸三カルシウム結合配列を含むポリペプチドとその使用
JP2022545185A (ja) * 2019-08-20 2022-10-26 セラダプティブ インク 骨インプラントにおける係留可能なタンパク質の送達のための材料

Also Published As

Publication number Publication date
JP2026004340A (ja) 2026-01-14
KR102821039B1 (ko) 2025-06-13
US20250179136A1 (en) 2025-06-05
EP4135750A4 (en) 2024-08-21
CN115916239A (zh) 2023-04-04
AU2021254751B2 (en) 2025-01-30
US12264187B2 (en) 2025-04-01
AU2021254751A1 (en) 2022-11-17
EP4135750A2 (en) 2023-02-22
BR112022020809A2 (pt) 2023-02-23
WO2021211683A2 (en) 2021-10-21
KR20230011289A (ko) 2023-01-20
TW202203961A (zh) 2022-02-01
US20230235002A1 (en) 2023-07-27
WO2021211683A3 (en) 2021-11-18
CA3180156A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
US11773138B2 (en) Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
KR102821039B1 (ko) 골에의 표적화된 치료적 전달을 위한 조성물 및 방법
Vukicevic et al. The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing
Oryan et al. Bone injury and fracture healing biology
Schützenberger et al. The optimal carrier for BMP-2: a comparison of collagen versus fibrin matrix
Kim et al. Promising efficacy of Escherichia coli recombinant human bone morphogenetic protein-2 in collagen sponge for ectopic and orthotopic bone formation and comparison with mammalian cell recombinant human bone morphogenetic protein-2
WO1998031788A1 (en) Injectable formulations for treatment of osteoporotic bone
Tanjaya et al. The effects of systemic therapy of PEGylated NEL-like protein 1 (NELL-1) on fracture healing in mice
US20230203115A1 (en) Therapeutic compositions comprising graft materials and beta-tcp binding peptides and uses thereof
Southwood et al. Evaluation of direct in vivo gene transfer in an equine metacarpal IV ostectomy model using an adenoviral vector encoding the bone morphogenetic protein‐2 and protein‐7 gene
CN113226386A (zh) 具有由多种电纺纤维形成的棉絮状结构的骨再生材料
Li et al. Repair of large segmental bone defects in rabbits using BMP and FGF composite xenogeneic bone
Masuda et al. Combined administration of BMP-2 and HGF facilitate bone regeneration through angiogenic mechanisms
HK40090498A (en) Compositions and methods for targeted therapeutic delivery to bone
HK40056601A (en) Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
HK40056601B (en) Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
Markel et al. Biologic Agents to Enhance Fracture Healing
Boerckel Mechanical regulation of bone regeneration and vascular growth in vivo
Lee A Pilot Study to Compare the Activity of Different Bone Morphogenetic Protein Bioimplants In Vivo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240412

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250512